Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe - Université de Tours Accéder directement au contenu
Article Dans Une Revue Basic and Clinical Pharmacology and Toxicology Année : 2024

Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe

Résumé

Abstract The European Cooperation in Science and Technology (COST) action ENOTTA (The European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases) was launched in 2022. To pave the way for harmonization of analytical methods for quantitation of serum levels of therapeutic antibodies in research and clinical settings, ENOTTA recently performed an online survey mapping laboratories in the field. The survey, which contained 30 questions surrounding therapeutic drug monitoring of relevant drugs and anti‐drug antibodies, was distributed via the ENOTTA and European Federation of Clinical Chemistry and Laboratory networks. Among 63 respondents across Europe, 45 reported analytical activity, with a range of utilized methods. Future engagement of as many sites as possible will enable comparison of methodologies and facilitate progress in the field.

Dates et versions

hal-04448240 , version 1 (09-02-2024)

Identifiants

Citer

Silje Skrede, Nataša Bogavac-Stanojević, Erwin Dreesen, Elisabet Nielsen, Martina Zaninotto, et al.. Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe. Basic and Clinical Pharmacology and Toxicology, 2024, ⟨10.1111/bcpt.13983⟩. ⟨hal-04448240⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More